Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028065 | 0.82 | MAPT (0.62) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5008268 | 0.81 | MAPT (0.61) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL19900671 | 0.80 | KMT2A (0.78) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL16697507 | 0.79 | MAPT (0.63) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL16697505 | 0.79 | MAPT (0.63) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL399793 | 0.76 | RAB9A (0.61) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL1021624 | 0.75 | MAPT (0.55) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL3502303 | 0.75 | MAPT (0.62) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL118567 | 0.75 | KMT2A (0.64) | MAPTKDM4ERAB9AKMT2ANPC1 | |
| SCHEMBL1673852 | 0.75 | KMT2A (0.64) | MAPTKDM4ERAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| EP-1858900-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2006097691-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1286988-A2 | 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-20010047017-A1 | Azole derivatives | HOFFMANN-LA ROCHE, INC. | 2001-11-29 | — | — | US | disclosed |
| US-6319933-B1 | 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives; fungicides | BASILEA PHARMACEUTICA AG (CH) | 2001-11-20 | — | — | US | disclosed |
| WO-2001079196-A2 | 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047017-A1 | Azole derivatives | ERG28, CYP51A1, CYP3A5 | MAPT 2247/4885KDM4E 1105/4885RAB9A 1880/4885 |
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | MAPT 1974/4885KDM4E 2614/4885RAB9A 2403/4885 |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | MAPT 196/4885KDM4E 2424/4885RAB9A 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.